A partnership has been agreed to develop multiple new products using Medherant technology developed by University of Warwick chemistry researchers
Midlands Medictech company Medherant has signed a partnership agreement with Cambridge-based Cycle Pharmaceuticals to develop multiple new products using Medherant technology developed by University of Warwick chemistry researchers.
Coventry-based Medherant's TEPI Patch Technology uses transdermal delivery technology (a patch that can simply be applied to the skin) and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients
Cycle will use Medherant's TEPI Patch transdermal delivery technology with drugs that will help patients' with conditions such as dysphagia and dyskinesia.
Some of the benefits of the TEPI Patch technology include less frequent drug administration, a possibility of reduced side effects through reducing peaks in drug concentrations, avoidance of gastrointestinal side effects and ease of use for the patient making it easier for them to stick to the prescribed treatments.
Work will commence immediately on the first two product development projects, which will be reformulations of The labs making a patch at the University of Warwickproducts used to treat rare neurological disorders, an area where improvements in ease of use are vital for compliance and quality of life. The agreement enables Cycle and Medherant to pursue further multiple products. Following TEPI Patch formulation development by Medherant, Cycle will be responsible for clinical development and registration, and will commercialise the products arising from this collaboration.
John Burt, Medherant's CEO said: "This collaboration with Cycle demonstrates the potential of the TEPI Patch technology to create differentiated products to address the needs of patients with rare diseases. We are looking forward to working with the excellent team at Cycle to progress these products into development."
Commenting on the agreement, Antonio Benedetti, CEO of Cycle said: "Cycle's core mission is to improve rare disease medicines to make them more effective, easier to take and to improve the quality of life of patients. This key agreement is aligned with Cycle's global alliances strategy which underpins our expanding rare disease product pipeline. We are proud to be partnering with Medherant."